How does the 2018 pipeline compare to 2017’s? In Vivo’s 2018 pipeline infographic examines pipelines by therapeutic area, company and phase. Find out which therapeutic areas are growing, which are shrinking, and which pharma companies have the most robust portfolios.
Author: Ian Lloyd
Published: 28 May 2018
Number of pages:2
How does the 2018 pipeline compare to 2017’s? Cancer remained the top therapy group in 2018, with a 7.6 percent increase in the number of therapeutic candidates–almost three times the growth of pipeline overall. That’s one key takeaway from In Vivo’s 2018 pipeline infographic, which examines the active drug pipeline by therapeutic area, company and phase. In terms of companies, Novartis topped the list for a second year running with 223 drugs in its pipeline, despite the fact it dropped by 28 drugs. Find out which of the top 10 pharmaceutical companies, by size of pipeline, increased their portfolio sizes and how the overall pipeline breaks down by phases.
This is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.